Pyx Health combats loneliness and addresses SDOH with an innovative combination of science, technology, and human connection. TT Capital is the lead strategic investor in Pyx Health.

Industry Advisor for Healthcare sector. Not exclusive.

CEO of InformedDNA (www.InformedDNA.com), a leading authority in the appropriate use of genetic testing serving health plans, health systems, employers, clinicians, and patients. Key offerings include clinical genetic counseling, genetic testing utilization management, genetic testing payment integrity, and expert genetics support for clinical trials. ❖ Structured merger with gWell and realignment of leadership team, including hiring new CEO and adding key member engagement technology.❖ Led restructuring of company after loss of largest client – negotiating exit terms, right-sizing employee base, refinancing debt, and raising bridge capital from current investors.❖ Transitioned organization and culture to blend clinical mission and financial outcomes. Company achieved financial budget and goals each year through disciplined metric management and proactive leadership.❖ Guided strategic shift of company to proactive engagement of health plan members to achieve improved outcomes through effective use of genetic testing.

I was hired to lead operational and financial strategy to support rapid growth – I built out the leadership team, established metrics/OKR-driven performance culture, and institutionalized cross-functional collaboration (i.e., broke down silos). I oversaw Data & Analytics, IT/Engineering, Customer Acquisition, and Clinical Network & Operations areas. I managed a team of of ~400+ headcount and 600+ providers. Among my achievements:❖Positioned company for successful majority investment by Optum (5/2020)❖Grew network capacity by while maintaining exceptional results in clinical outcomes, capacity availability, and member Net Promoter Score (NPS) measures.❖Reduced cost of member acquisition by while increasing enrollment productivity. Improved unit economics dramatically by instituting consumer acquisition best practices, rationalizing targeting models, and enhancing overall data quality.❖Spearheaded Medicare Advantage growth by resolving major compliance/security gaps and realigning value proposition. Led the organization to achieve HITRUST Certification and pass all Medicare Advantage audits.❖Led efforts to acquire (3/2019) and integrate Joyable, an eCBT company with an industry-leading, evidence-based treatment application. Positioned AbleTo to treat full employer populations in a highly cost-effective manner, accelerating growth and population penetration.

I was hired as Altegra Health's 1st COO, contributing to big-picture strategy development and supporting the process of the company sale to Change Healthcare. I addressed and resolved critical operational and integration issues. I led a team of up to 8 direct and approximately 1,100 indirect reports, and managed a ~$110M annual budget. I served as the primary point person for program management matters, as well as the Executive Sponsor for key clients. Past successes:❖Played key role in $900M sale of Altegra Health to Change Healthcare (FKA Emdeon) in 8/2015 and resultant integration.❖Achieved 20% reduction in unit costs for Chart Retrieval & Clinical Review operations. Built B2B call center & rationalized coding guidelines.❖Generated 22% increase in Medicaid approvals per FTE yield by leading a reimagining and revamp of the Member Engagement business, applying detailed analytics to shift the investment and operating paradigm.❖Drove significant improvement in client satisfaction -- reorganized service management, instituted NPS measures, and achieved a 30% reduction in watch-list accounts.

As CQO, I transitioned to critical-need area to drive dramatic quality improvement for the Medicare Advantage business. I held full accountability for the Stars program (rating from Medicare regarding health plan’s quality and performance), Pharmacy Operations, Revenue Management, and Internal Audit functions. I am proud to have:❖Advanced Star ratings for all 9 plans in a 2-year period, with a 20% overall Star rating increase from 3.0 to 3.6 (largest increase of any publicly traded insurance company at the time). Facilitated 4-Star ratings for the 2 largest plans that represented 75% of the core membership, resulting in 5% of revenue bonus key to the plan’s competitive position. Outcomes included: 30% increase in “Managing Chronic Conditions” Star measures; and 35% improvement in key health plan Member Experience Survey.❖Led the full-scale redesign of the Pharmacy Organization and oversight of PBM resulting in 92% improvement in member service levels, successful transition to tiered generic formulary, and 50% decline in grievances (all accomplished in <18 months).

As head of Corporate Operations, I oversaw multiple departments that included Operations (Medicare Advantage & Part D), Procurement, Facilities, Corporate Analytics, Performance Improvement, Internal Audit, and HR. I managed ~$140M budget and led a team of seven direct reports and ~1,000+ indirect FTEs (including offshore vendors). Key highlights:❖Achieved $40M operations cost decrease. Rationalized and streamlined 9 call center operations, led off-shoring initiatives, improved vendor management, and optimized print fulfillment.❖Secured release from sanction in less than 9 months for Medicare Advantage plan, representing one of the shortest timespans in CMS history, through a series of executive transformation initiatives.

I was brought on board to leverage prior PE experience to build out the portfolio team and strategy. I oversaw seven portfolio companies that represented $9B in revenues and a $1B EBITDA. I coached executive teams, redesigned the investment portfolio review process, and championed the introduction of best practices. Notably, I:❖Influenced $197M in cost reductions through strategic guidance of required initiatives; specifics included: Bausch & Lomb ($120M); Universal American ($65M); and Vision Logistics ($12M).❖Provided strategic guidance for multiple integrations, including Renal Advantage/National Renal Alliance, Vision Logistics, and OHL International; identified $35M in targeted savings for Multiplan/Viant merger.

I launched a 100-day plan for spin-off of 400-person insurance TPA from Zurich Financial Services as a Board Member and Business Advisor. I served as Executive Vice Chairman, interim CEO, and Board Member for PeopleKeep (FKA Zane Benefits).

I led key business activities of 140-person company, including creation of business plans, management processes, and leadership goals. I expanded the company annual lease right investments by 17% in 12 months and influenced a 2.1x ROI for PE investor via sale of wireless lease portfolio.

Oversee portfolio management activities for private equity fund focused on financial services investments. Lead investment diligence, strategic and turnaround initiatives for portfolio companies. Active Board member. Board positions include Lendingtree, Aames Financial Corporation, Digital Insurance, and Ultralink.I co-led the turnaround of Aames Investment Corporation, leading to profitability and $500M capital raise for conversion to public REIT and subsequent merger with Accredited. I contributed as an active board member to growing Lending Tree’s annual revenues from $7M to $140M, leading to the company’s sale to the Interactive Corporation. I managed the sale process of Derivion to Metavante and Ultralink to Secova.========================================================ADDITIONAL EXPERIENCEAT&T Capital/Newcourt Credit Group, SVP Business Development & Strategic PlanningGE Capital Services, SVP Business DevelopmentBankers Trust, VP Management Consulting GroupBain & Company, Consultant (funded MBA)Price Waterhouse (PWC), Consultant